Grey Wolf Therapeutics
Generated by Meeveem AI
"Developing first in class antigen modulators to control T cell activation and treat immune disease"
Abingdon
•11 - 50 Employees
•Biotechnology
About Grey Wolf Therapeutics
Greywolf Therapeutics develops antigen modulators, a new class of treatments that address immune dysfunction at its source. Many diseases, including cancers, autoimmune disorders, and infectious diseases, arise or resist treatment because T cells cannot recognise or target cells correctly. Greywolf's technology modulates antigen presentation, altering how cells appear to the immune system. The company's lead candidate, GRWD5769, is progressing through Phase 1/2 clinical trials in oncology, demonstrating proof of mechanism. Greywolf operates discovery and development programmes across oncology, autoimmunity, and virology. Headquartered in Abingdon, UK, the company advances treatments that mark a fundamental shift in addressing immune dysfunction.
45
Team Members
2017
Founded
Biotechnology
Sector
Hybrid
Work Environment
Our Vision
A world where immune dysfunction no longer drives disease, where T cells can be precisely guided to recognise and target the right cells, enabling the body's own defences to protect against cancers, autoimmune disorders, and infections.
Our Mission
Greywolf Therapeutics progresses first in class antigen modulators to treat people living with cancers, autoimmune disorders, and infectious diseases by controlling T cell activation.